Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|January 19, 2017
Drug Cost Growth Changing the Specialty Pharmacy Patient Experience
Author(s)Lauren Santye, Assistant Editor
Marc O'Connor, CEO and chief strategy officer of Curant Health, discusses how projected drug spending growth will alter the specialty pharmacy landscape in the future.
Advertisement
Marc O'Connor, CEO and chief strategy officer of Curant Health, discusses how projected drug spending growth will alter the specialty pharmacy landscape in the future.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
3
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
4
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
5